In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leading In Product Development Means Planning For All Eventualities

Using Failure Investigation Data Earlier In Product Development

Executive Summary

What is the cost of an adverse event, and the resulting safety action for a medical device that is already on the market? It is the kind of question that no company with products on the market wants to have to confront, but it is also one they know they should plan for, says the design consultancy and innovation organization NCS Lab srl.

You may also be interested in...



ConMed’s Ortho Franchise Prioritizes Pipeline Over External Growth

ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.

Leading Medtechs See Organic Growth Across A Market In Flux

In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.

ConMed’s ‘No Smoking’ Drive Has Multiple Benefits In General Surgery

ConMed Corp. is company of two halves  ̶  general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.

Topics

UsernamePublicRestriction

Register

IV124262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel